Gainers
Iterum Therapeutics plc (NASDAQ: ITRM) rose 30.1% to $1.60 in pre-market trading after the company issued an update on NDA review for sulopenem etzadroxil/probenecid….
Iterum Therapeutics plc (NASDAQ: ITRM) rose 30.1% to $1.60 in pre-market trading after the company issued an update on NDA review for sulopenem etzadroxil/probenecid….
